Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00521261 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]